55 TWENTYFOURSEVENBIOPHARMA Issue 1 / March 2025 ONESOURCE According to Sharma, this complexity is prohibitive for many CDMOs that may be interested in entering the drug-device space. OneSource has found tremendous success in this niche, and the company is actively working on nine products in the biologics, peptides, and non-peptides spaces, including three GLP-1 projects with global pharmaceutical leaders. GLP-1s, one of the hottest topics in Milan amid the widespread success of drugs like Ozempic, is one emergent technology OneSource is equipped to work with. Sharma noted that whether its GLP-1s, drug-device combinations, Biologics or Soft Gelatin Capsules, by investing in robust technological processes the company is prepared to pivot to whatever the industry demands. “The Strides group is known for significant investments in CapEx in the latest technologies,” said Sharma. “We partnered with Pharmagel for Soft gelatin capsules in 90s, invested in isolator technology, in sterile injections, way back in 2015, 2016, when nobody really was looking for it, started working on GLP-1s in 2019Only now FDA is wanting more and more sites to be isolator based, but we invested in that technology. So the group is known for investing in absolute hightech equipment well ahead of before it becomes a trend. We have never shied away from investment, and we have never really been worried about where the funding is going to come from.” Similarly, the company is also looking to capitalize on regulatory trends in the broader biopharma market. The pending BIOSECURE Act is positioned to encourage friendshoring, and companies like Onesource are positioned to have a geographic advantage among US-friendly countries due to their relatively low manufacturing costs. “Finding an alternative to China has already begun, and that continues with or without [BIOSECURE],” said Sharma. “We have seen over the last eight months or so, we have had multiple American multinationals, Japanese multinationals, coming over... we have, right now, multiple open request for proposals (RFPs) from some of the renowned companies on biologics, drug substance, and drug products.” “So, if you ask me, will all those RFPs close? No. But will some of the RFPs close? Absolutely. We’ll get that business, and if you and I have this pleasure of meeting two years from now, you will see multiple Indian companies, including Onesource, having some good business coming which was maybe originally for China— both as a second source for existing products, and certainly for new products.” GRANT PLAYTER Editor 24/7 BIOPHARMA
RkJQdWJsaXNoZXIy MjY2OTA4MA==